Nicht-alkoholische Fettlebererkrankung (NAFLD)

Rau, Monika; Weiß, Johannes; Geier, Andreas

doi:10.1055/s-0041-102787

Cited by 9 publications

(3 citation statements)

References 22 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2,3] NAFLD encompasses a spectrum of pathological processes ranging from simple fatty liver, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. [4] Although it is well-recognized that obesity, insulin resistance, and metabolic syndrome may influence the development and progression of NAFLD, inherited factors, and in particular single nucleotide polymorphisms (SNPs) in genes could play a significant role in the severity of liver disease and the susceptibility to NAFLD. [5–7] …”

Section: Introductionmentioning

confidence: 99%

Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population

Song

Xiao²,

Wang³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population

Song

Xiao²,

Wang³

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…MAFLD is a medical condition defined by the abnormal accumulation of fat within liver cells. The main reasons contributing to its development are hyperinsulinemia, resistance to insulin, increased lipolysis in peripheral tissues, and an imbalance of the redox system causing oxidative stress 2 – 4 .…”

Section: Introductionmentioning

confidence: 99%

A study of the relationship between serum asprosin levels and MAFLD in a population undergoing physical examination

Lv,

Wang,

Meng

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Asprosin, an adipokine, was recently discovered in 2016. Here, the correlation between asprosin and metabolic-associated fatty liver disease (MAFLD) was examined by quantitatively assessing hepatic steatosis using transient elastography and controlled attenuation parameter (CAP). According to body mass index (BMI), 1276 adult participants were enrolled and categorized into three groups: normal, overweight, and obese. The study collected and evaluated serum asprosin levels, general biochemical indices, liver stiffness measure, and CAP via statistical analysis. In both overweight and obese groups, serum asprosin and CAP were greater than in the normal group (p < 0.01). Each group showed a positive correlation of CAP with asprosin (p < 0.01). The normal group demonstrated a significant and independent positive relationship of CAP with BMI, low-density lipoprotein cholesterol (LDL-C), asprosin, waist circumference (WC), and triglycerides (TG; p < 0.05). CAP showed an independent positive association (p < 0.05) with BMI, WC, asprosin, fasting blood glucose (FBG), and TG in the overweight group, and with high-density lipoprotein cholesterol (HDL-C) showed an independent negative link (p < 0.01). CAP showed an independent positive relationship (p < 0.05) with BMI, WC, asprosin, TG, LDL-C, FBG, glycated hemoglobin A1c (HbA1c), and alanine transferase in the obese group. CAP also showed an independent positive link (p < 0.01) with BMI, WC, asprosin, TG, LDL-C, and FBG in all participants while independently and negatively correlated (p < 0.01) with HDL-C. Since asprosin and MAFLD are closely related and asprosin is an independent CAP effector, it may offer a novel treatment option for metabolic diseases and MAFLD.

show abstract

“…NAFLD in the background of overweight or obesity suggests disorders of adipose tissue secretion of hormones adipokines, which reduces tissue sensitivity to insulin by reducing adiponectin levels and increasing levels of visfatin and resistin, as well as increasing the level of chemokines that activate macrophages and promote their accumulation in fatty tissue. Activated macrophages produce cytokines that negatively affect sensitivity to insulin [5].…”

mentioning

confidence: 99%

Parameters of Lipid Metabolism and Severity of Liver Steatosis in Patients With Non-Alcoholic Fatty Liver Disease on the Background of Hypertension Depending on the Status of Carbohydrate Metabolism

Babak,

Bashkirova

2019

ISMS

View full text Add to dashboard Cite

The aim of the study was to establish relationships between the parameters of lipid metabolism, the severity of liver steatosis and the concentration of endothelial lipase (EL) serum levels depending on the state of carbohydrate metabolism and the presence of type 2 diabetes .60 patients with non-alcoholic fatty liver disease (NAFLD) on the background of hypertension and overweight have been examined. The distribution of the examined patients was carried out in the following groups: group 1 - patients with hypertension without an increase in NAFLD liver fat score normal weight (n = 8); Group 2 - with hypertension without increse in NAFLD liver fat score with overweight (n = 8); group 3 - with liver steatosis without type 2 diabetes (n = 10); group 4 - with liver steatosis and type 2 diabetes (n = 10); group 5 - with laboratory signs of steatohepatitis without type 2 diabetes (n = 16); group 6 - with laboratory signs of steatohepatitis and type 2 diabetes (n = 8). All patients were divided with accordance of age and sex. The control group consisted of 20 healthy individuals.All patients with NAFLD on the background of hypertension and the presence of type 2 diabetes had significantly (p <0.001) higher hyperinsulinism (32.27 + 4.71 vs. 20.75 + 9.5 mkU/ml) and significantly (p <0.001) increased values of insulin resistance index HOMA-IR (9.52 + 4.21 against 4.76 + 2.23 U), which testifies in favour of type 2 diabetes.In all patients with NAFLD on the background of hypertension, there are proatherogenic changes in lipid status, the presence of which is exacerbated with obesity and the severity of steatosis. It is most evident in patients with steatohepatitis in combination with type 2 diabetes.The level of EL is significantly higher in patients with steatosis, regardless of the presence of diabetes and with steatohepatitis without diabetes compared with controls and patients with hypertension and normal weight. Significantly high levels of endothelial lipase were found in patients with steatohepatitis and diabetes. Correlation analysis between the HbA1c and EL levels showed a reliable direct relationship between the parameters.So the level of EL in patients with hypertension in combination with the severity of liver steatosis is significant relative to atherosclerotic vascular lesions and prognostic as the occurrence of cardiovascular complications.Keywords: NAFLD, hypertension, type 2 diabetes, endothelial lipase, insulin resistance

show abstract

Nicht-alkoholische Fettlebererkrankung (NAFLD)

Cited by 9 publications

References 22 publications

Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population

Association of patatin-like phospholipase domain-containing protein 3 gene polymorphisms with susceptibility of nonalcoholic fatty liver disease in a Han Chinese population

A study of the relationship between serum asprosin levels and MAFLD in a population undergoing physical examination

Parameters of Lipid Metabolism and Severity of Liver Steatosis in Patients With Non-Alcoholic Fatty Liver Disease on the Background of Hypertension Depending on the Status of Carbohydrate Metabolism

Contact Info

Product

Resources

About